234 related articles for article (PubMed ID: 10354600)
1. Recent advances in understanding the pathogenesis of Huntington's disease.
Reddy PH; Williams M; Tagle DA
Trends Neurosci; 1999 Jun; 22(6):248-55. PubMed ID: 10354600
[TBL] [Abstract][Full Text] [Related]
2. [Huntington's disease: clinical and molecular genetics].
Warita H; Shiro Y; Kashihara K; Abe K
Nihon Rinsho; 1999 Apr; 57(4):896-9. PubMed ID: 10222786
[TBL] [Abstract][Full Text] [Related]
3. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.
Reddy PH; Williams M; Charles V; Garrett L; Pike-Buchanan L; Whetsell WO; Miller G; Tagle DA
Nat Genet; 1998 Oct; 20(2):198-202. PubMed ID: 9771716
[TBL] [Abstract][Full Text] [Related]
4. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene.
Ishiguro H; Yamada K; Sawada H; Nishii K; Ichino N; Sawada M; Kurosawa Y; Matsushita N; Kobayashi K; Goto J; Hashida H; Masuda N; Kanazawa I; Nagatsu T
J Neurosci Res; 2001 Aug; 65(4):289-97. PubMed ID: 11494364
[TBL] [Abstract][Full Text] [Related]
6. Mouse models of Huntington's disease.
Menalled LB; Chesselet MF
Trends Pharmacol Sci; 2002 Jan; 23(1):32-9. PubMed ID: 11804649
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial structural and functional dynamics in Huntington's disease.
Reddy PH; Mao P; Manczak M
Brain Res Rev; 2009 Jun; 61(1):33-48. PubMed ID: 19394359
[TBL] [Abstract][Full Text] [Related]
8. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
Hannan AJ
Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
[TBL] [Abstract][Full Text] [Related]
9. Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.
Dallérac GM; Levasseur G; Vatsavayai SC; Milnerwood AJ; Cummings DM; Kraev I; Huetz C; Evans KA; Walters SW; Rezaie P; Cho Y; Hirst MC; Murphy KP
Neurodegener Dis; 2015; 15(2):93-108. PubMed ID: 25871323
[TBL] [Abstract][Full Text] [Related]
10. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy.
Sawiak SJ; Wood NI; Morton AJ
J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335
[TBL] [Abstract][Full Text] [Related]
11. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
Podvin S; Reardon HT; Yin K; Mosier C; Hook V
J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
[TBL] [Abstract][Full Text] [Related]
12. Huntington's disease as caused by 34 CAG repeats.
Andrich J; Arning L; Wieczorek S; Kraus PH; Gold R; Saft C
Mov Disord; 2008 Apr; 23(6):879-81. PubMed ID: 18307262
[TBL] [Abstract][Full Text] [Related]
13. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
14. Bioenergetics in Huntington's disease.
Grünewald T; Beal MF
Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for the onset and progression of Huntington disease.
Chao TK; Hu J; Pringsheim T
Neurotoxicology; 2017 Jul; 61():79-99. PubMed ID: 28111121
[TBL] [Abstract][Full Text] [Related]
16. Huntington's Disease: Relationship Between Phenotype and Genotype.
Sun YM; Zhang YB; Wu ZY
Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics of Huntington's Disease.
Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
[TBL] [Abstract][Full Text] [Related]
18. The molecular biology of Huntington's disease.
Ho LW; Carmichael J; Swartz J; Wyttenbach A; Rankin J; Rubinsztein DC
Psychol Med; 2001 Jan; 31(1):3-14. PubMed ID: 11200958
[TBL] [Abstract][Full Text] [Related]
19. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
[TBL] [Abstract][Full Text] [Related]
20. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
